Loading
A phase 3 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer is a phase 3 interventional study registered as NCT05855200 by GlaxoSmithKline, with 892 participants planned, started 2023-08-01 and due to reach its primary completion in 2029-03-19. Interventions recorded: Dostarlimab, CAPEOX and FOLFOX.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Colorectal cancer and the tag pipeline.
Shares Dostarlimab, GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Making microsatellite-stable colorectal cancer immunotherapy-responsive, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/